Skip to main content
. Author manuscript; available in PMC: 2022 Jan 18.
Published in final edited form as: Mucosal Immunol. 2021 Aug 21;15(1):74–83. doi: 10.1038/s41385-021-00441-3

Figure 4. Knockdown of PTPN2 inhibits IL-6-mediated promotion of IL-4 signaling and alternative macrophage activation.

Figure 4.

THP-1 cells expressing non-targeting control (shCtr) or PTPN2-specific (shPTPN2) shRNA were differentiated into macrophages and treated with IL-6 for 6 h prior to treatment with IL-4 for 30 minutes (A) or 24 h (B-D). The graphs show A) representative Western blot images for the indicated proteins, B) mRNA expression of MRC1 (encoding CD206), IL10 and TGFB, RETN, ALOX15; C) flow cytometry for CD206 surface expression (gated on live, single cells), and D) IL-10 and TGFβ and resistin levels in the cell culture medium. ** = p < 0.01 relative to untreated control cells, ANOVA with Dunnetts’s multiple comparisons test. Representative results from three independent experiments with 5 independent replicates (n=5).